We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

4 hedge funds and large institutions have $9K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more capital invested

Capital invested by funds: $9K → $9K ($0)

20% less funds holding

Funds holding: 54 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
Reduced
Closed
2
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

Rank Fund Capital Flow
1
LIA
LBMC Investment Advisors
Tennessee
+$1K

Top Sellers

Rank Fund Capital Flow
1
BO
BRR OpCo
Ohio
-$2K

PVCT Hedge Fund Activity: Q1 2019 in Review

4 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2019, worth a combined $9K — unchanged from a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PVCT and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was LBMC Investment Advisors, opening a new position worth an estimated $1K. The largest seller was BRR OpCo, exiting entirely with an estimated $2K sold.

  • 4 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2019, down from 5 in Q4 2018.
  • Funds reported $9K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2019, unchanged quarter-over-quarter.
  • 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2019 and 2 closed out, a net change of -1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q1 2019 was LBMC Investment Advisors, an estimated $1K added.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q1 2019 was BRR OpCo, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2019.